
PharmiWeb Today Story
- Support to include dedicated educational website, science advisory panel, patient video series and strategic alliance across sleep patient advocacy organizations
- Research shows that sleep disorders are associated with increased risks of cardiovascular comorbidities, including those with narcolepsy being two- to three-times more likely to have a stroke or heart attack than people without narcolepsy
DUBLIN, March 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an expansion of its support of the American Heart Association (Association) to provide the sleep disorder community an in-depth understanding of the cardiovascular risks associated with these debilitating disorders. Through this initiative, the Association aims to help people living with sleep disorders determine when professional help may be appropriate and healthcare professionals recognize ways to improve heart health for the patients they treat.
An estimated 50 million to 70 million American adults have a chronic, or ongoing, sleep disorder.1 Studies have shown that poor sleep quality and duration can be associated with high blood pressure, elevated cholesterol, stroke and heart attacks.2
"With more than two decades of scientific research in complex and difficult-to-treat neurological conditions, we have long been at the forefront of pr…
Read More...
Articles

7 Ways to Get Your Jobs in Front of More People
23-Mar-2023

9 Ways to Become a Better Pharma Recruiter
10-Mar-2023

What Does a Clinical Trials Manager (CTM) Do?
08-Mar-2023
Featured Events

-
Reuters Events: Cell & Gene Therapy USA 2021
28-Sep-2021 - 29-Sep-2021 -
Reuters Events: Pharma 2021
11-Oct-2021 - 22-Oct-2021 -
HFpEF Drug Discovery & Development Summit 2022
25-Jan-2022 - 27-Jan-2022 -
Pharma USA 2022
16-Mar-2022 - 17-Mar-2022 -
Bioprocessing and the future of food
06-Jul-2022 - 07-Jul-2022 -
How to impact, influence & inspire
07-Feb-2023 - 21-Feb-2023
News

-
FSD Pharma Announces Filing of Year-End 2022 Resul…
01-Apr-2023 -
PAION AG implements resolved capital reduction
31-Mar-2023 -
TOPTICA is growing
31-Mar-2023 -
The Brains Marketing Group Launches Rocket Healthc…
31-Mar-2023 -
MediClin AG: Group sales and Group operating resul…
31-Mar-2023 -
LEADING MICROBIOLOGY TESTING FACILITY INVESTS IN T…
31-Mar-2023